Omega Healthcare reports Q4 adusted FFO 74, consensus 73c

Reports Q4 revenue $279.3M, consensus $278.6M. Taylor Pickett, Omega’s CEO, stated, “In the fourth quarter, we were again able to increase FAD per share sequentially, while continuing to de-lever the balance sheet. 2024 was a strong year for Omega. We were able to accretively invest over $1.1 billion, grow FAD per share, reduce the dividend payout ratio, and reduce leverage from 5 times to below 4 times. The backdrop continues to be favorable. Operating metrics remain strong, with both occupancy and coverage modestly improving in the quarter. The pipeline remains very active, and we have a cost of capital that should allow us to continue to accretively invest. As often happens, the change of administration has raised questions around the regulatory and reimbursement environment. While it’s too early to know what, if any, changes may occur, the current administration was very supportive of the industry during their last term, and we look forward to working with them to continue to support the aging population within our communities.”